Back

Laboratory of Molecular Oncology

What are distinctive features of modern molecular cancer researches?

The purpose of performing of molecular cancer researches of the previous era was to deepen the understanding of cancer development. At present the vast majority of molecular cancer researches is designed for development of more effective anti-cancer therapy strategies.

While performing modern researches, cancer researchers accumulate far more data, so the probability increases to obtain clinically significant results of the researches, the implementation of which in the Clinic is also significant.

Experimental and clinical studies are performed in the laboratory. Technologies of total researches are implemented, new generation sequencing technologies, modern modelling systems (infrastructure of cell cultivation in monolayer and spatial cultures) are applied, and experience of researches using patient biomaterials is accumulated.

Research areas:

  1. Search for molecular cancer markers for cancer diagnosis, prognosis, and individualization of treatment, is based on cancer biology knowledge.
  2. The objective is a better understanding of molecular processes occurring in cancer cells and in organisms of patients during anti-cancer therapies for development of strategies of more effective anti-cancer therapy.

Projects:
  1. Indentification of cancer progression associated circulating miRNA for disease prognosis and evaluation of the effectivity of anticancer therapy (2015-2018, Head Prof. N. E. Samalavičius).
  2. Development of the molecular tool for determination of thyroid follicular carcinoma. (2017-2019, Head Dr. K. Sužiedėlis).
  3. Assessment of brain tumors prognostic factors and early response to treatment by imaging biomarkers (2014-2017, Head Dr. E.Aleknavičius).
Publications:

2019

  1. Stakišaitis D, Juknevičienė M, Damanskienė E, Valančiūtė A, Balnytė I, Alonso MM. The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo. Cancers (Basel). Cancers (Basel). 2019 Aug 20;11(8). doi: 10.3390/cancers11081210. (IF=6,162)
  2. Stakišaitis D, Zamarytė-Sakavičienė K, Lesauskaitė V, Jankūnas RJ. Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy. Ther Innov Regul Sci. 2019 Jul;53(4):549-553. doi: 10.1177/2168479018795857. (IF=0,901)
  3. Juknevičienė M, Balnytė I, Valančiūtė A, Lesauskaitė V, Stanevičiūtė J, Curkūnavičiūtė R, Stakišaitis D. Valproic Acid Inhibits NA-K-2CL Cotransporter RNA Expression in Male But Not in Female Rat Thymocytes. Dose Response. 2019 May 30;17(2):1559325819852444. doi: 10.1177/1559325819852444. (IF=2,435)
  4. Stanevičiūtė J, Juknevičienė M, Balnytė I, Valančiūtė A, Lesauskaitė V, Fadejeva J, Stakauskas R, Stakišaitis D. Gender-Related Effect of Sodium Dichloroacetate on the Number of Hassall's Corpuscles and RNA NKCC1 Expression in Rat Thymus. Biomed Res Int. 2019 Apr 24;2019:1602895. doi: 10.1155/2019/1602895. (IF=2,583)
  5. Kuciauskas D, Dreize N, Ger M, Kaupinis A, Zemaitis K, Stankevicius V, Suziedelis K, Cicenas J, Graves LM, Valius M. Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells. Cancers (Basel). 2019 Jul 11;11(7). doi: 10.3390/cancers11070972. (IF=6,162)
  6. Miškinytė M, Juškaitė R, Skerniškytė J, Voldemarienė V, Valuckas KP, Kučinskienė ZA, Sužiedėlis K, Sužiedėlienė E. High incidence of plasmid-mediated quinolone resistance (PMQR) genes among antibiotic-resistant Gram-negative bacteria from patients of the Lithuanian National Cancer Center. Infect Dis (Lond). 2019 Jun;51(6):471-474. doi: 10.1080/23744235.2019.1591637. (IF=1,932)

2018

  1. Stakišaitis D, Juknevičienė M, Ulys A, Žaliūnienė D, Stanislovaitienė D, Šepetienė R, Slavinska A, Sužiedėlis K, Lesauskaitė V. ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity. Oncol Lett. 2018 Jul;16(1):1321-1331. doi: 10.3892/ol.2018.8749. (IF=1,664)
  2. Stakišaitis D, Zamarytė-Sakavičienė K, Lesauskaitė V, Jankūnas RJ. Off-label use of antipsychotic agents in dementia: evidence for the revision of the reimbursement policy. Ther Innov Regul Sci. 2019 Jul;53(4):549-553. doi: 10.1177/2168479018795857. (IF=0,882)
  3. Stanevičiūtė J, Juknevičienė M, Palubinskienė J, Balnytė I, Valančiūtė A, Vosyliūtė R, Sužiedėlis K, Lesauskaitė V, Stakišaitis D. Sodium Dichloroacetate Pharmacological Effect as Related to Na–K–2Cl Cotransporter Inhibition in Rats. Dose Response. 2018 Nov 20;16(4):1559325818811522. doi: 10.1177/1559325818811522. (IF=2,435)
  4. Strainiene E, Binkis M, Urnikyte S, Stankevicius V, Sasnauskiene A, Kundrotas G, Kazlauskas A, Suziedelis K. Microenvironment dependent gene expression signatures in reprogrammed human colon normal and cancer cell lines. BMC Cancer. 2018 Feb 27;18(1):222. doi: 10.1186/s12885-018-4145-8. (IF=3,288)
  5. Skeberdytė A, Sarapinienė I, Aleksander-Krasko J, Stankevičius V, Sužiedėlis K, Jarmalaitė S. Dichloroacetate and salinomycin exert a synergistic cytotoxic effect in colorectal cancer cell lines. Sci Rep. 2018 Dec 10;8(1):17744. doi: 10.1038/s41598-018-35815-4. (IF=4,122)
  6. Šlekienė L, Stakišaitis D, Balnytė I, Valančiūtė A. Sodium valproate inhibits small cell lung cancer tumor growth on the chicken embryo chorioallantoic membrane and reduces the p53 and EZH2 expression. Dose Response. 2018 Apr 26;16(2):1559325818772486. doi: 10.1177/1559325818772486. (IF=2,435)
  7. Rynkeviciene R, Simiene J, Strainiene E, Stankevicius V, Usinskiene J, Miseikyte Kaubriene E, Meskinyte I, Cicenas J, Suziedelis K. Non Coding RNAs in Glioma. Cancers (Basel). 2018 Dec 22;11(1). doi: 10.3390/cancers11010017. (IF=6,162)
  8. Baltruskeviciene E, Kazbariene B, Aleknavicius E, Krikstaponiene A, Venceviciene L, Suziedelis K, Stratilatovas E, Didziapetriene J. Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment. Tumori. 2018 Oct;104(5):375-380. doi: 10.5301/tj.5000674. (IF=1,233)

2017

  1. Baltruskeviciene E, Schveigert D, Stankevicius V, Mickys U, Zvirblis T, Bublevic J, Suziedelis K, Aleknavicius E. Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding. BMC Cancer. 2017 Sep 1;17(1):607. doi: 10.1186/s12885-017-3575-z. (IF=3,288)
  2. Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K, Meskinyte-Kausiliene E, Stankevicius V, Valius M. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol. 2017 Feb;34(2):26. doi: 10.1007/s12032-016-0879-9. (IF=2,634)
  3. Stankevicius V, Kunigenas L, Stankunas E, Kuodyte K, Strainiene E, Cicenas J, Samalavicius NE, Suziedelis K. The expression of cancer stem cell markers in human colorectal carcinoma cells in a microenvironment dependent manner. Biochem Biophys Res Commun. 2017 Mar 18;484(4):726-733. doi: 10.1016/j.bbrc.2017.01.111. (IF=2,466)
  4. Stankevicius V, Kuodyte K, Schveigert D, Bulotiene D, Paulauskas T, Daniunaite K, Suziedelis K. Gene and miRNA expression profiles of mouse Lewis lung carcinoma LLC1 cells following single or fractionated dose irradiation. Oncol Lett. 2017 Jun; 13(6): 4190–4200. doi: 10.3892/ol.2017.5877. (IF=1,390)
  5. Stankevicius V, Vasauskas G, Rynkeviciene R, Venius J, Pasukoniene V, Aleknavicius E, Suziedelis K. Microenvironment and Dose-Delivery-Dependent Response after Exposure to Ionizing Radiation in Human Colorectal Cancer Cell Lines. Radiat Res. 2017 Sep;188(3):291-302. doi: 10.1667/RR14658.1. (IF=2,539)

2016

  1. Schveigert D, Krasauskas A, Didžiapetrienė J, Kalibatienė D, Cicėnas S. Smoking, hormonal factors and molecular markers in female lung cancer. Neoplasma. 2016;63(4):504-9. doi: 10.4149/neo_2016_402. (IF=1,961)
  2. Stankevicius V, Vasauskas G, Bulotiene D, Butkyte S, Jarmalaite S, Rotomskis R, Suziedelis K. Gene and miRNA expression signature of Lewis lung carcinoma LLC1 cells in extracellular matrix enriched microenvironment. BMC Cancer. 2016; 16:789. DOI 10.1186/s12885-016-2825-9. (IF=3,265)
  3. Stankevicius V, Vasauskas G, Noreikiene R, Kuodyte K, Valius M, Suziedelis K. Extracellular Matrix-dependent Pathways in Colorectal Cancer Cell Lines Reveal Potential Targets for Anticancer Therapies. Anticancer Res. 2016 Sep;36(9):4559-67. (IF=1,826)

2015

  1. Janulionis E, Valuckas KP, Liukpetryte S, Samerdokiene V, Atkocius V. Californium versus cobalt brachytherapy combined with external-beam radiotherapy for IIB stage cervical cancer: long-term experience of a single institute. J Contemp Brachytherapy. 2015 Oct;7(5):346-51. doi: 10.5114/jcb.2015.55117. (IF=1,284)
  2. Liubavičiūtė A, Krasko JE, Mlynska A, Lagzdina J, Sužiedėlis K, Pašukonienė V. Evaluation of low-dose proton beam radiation efficiency in MIA PaCa-2 pancreatic cancer cell line vitality and H2AX formation. Medicina (Kaunas). 2015 Nov;51(5):302-6. doi: 10.1016/j.medici.2015.10.002. (IF=0,494)
  3. Samerdokiene V, Valuckas KP, Janulionis E, Atkocius V, Rivard MJ. Second primary malignancies after radiotherapy including HDR 252Cf brachytherapy for cervical cancer. Brachytherapy. 2015 Nov-Dec;14(6):898-904. doi: 10.1016/j.brachy.2015.06.006. (IF=2,758)
  4. Samerdokiene V, Mastauskas A, Atkocius V. Assessment of annual average effective dose status in the cohort of medical staff in Lithuania during 1991-2013. Radiat Prot Dosimetry. 2015 Dec;167(4):671-7. doi: 10.1093/rpd/ncu368. (IF=0,913)

2014

  1. Schveigert D, Cicenas S, Bublevic J, Askinis R, Sapoka V, Didziapetriene J. The role of genetic and other biomarkers in NSCLC prognosis. Centr Eur J Med. 2014; 9(3):382–90. (IF=0,209)

2013

  1. Krasko JA, Maksimova I, Rudgalvytė M, Pašukonienė V. Radiation induced multidrug resistance in breast cancer – laboratory model. Proceedings of the 11th International Conference „Medical Physics in the Baltic States“. Kaunas, Lietuva. Technologija. 2013; 11:8–11.
  2. Lagzdina E, Gaspariūnas M, Plukienė R, Plukis A, Pašukonienė V, Sužiedėlis K, Kovalevskij V. The application of 1.6 MeV proton microbeam to investigate radiation-induced bystander effect in MIA PaCa-2 pancreatic cancer cell line. Proceedings of the 11th International Conference „Medical Physics in the Baltic States“. Kaunas, Lietuva. Technologija. 2013; 67–70.
  3. Povilonis J, Seputiene V, Krasauskas R, Juskaite R, Miskinyte M, Suziedelis K, Suziedeliene E. Spread of carbapenem-resistant Acinetobacter baumannii carrying a plasmid with two genes encoding OXA-72 carbapenemase in Lithuanian hospitals. J Antimicrob Chemother. 2013 May;68(5):1000-6. doi: 10.1093/jac/dks499. (IF=5,338)
  4. Samerdokienė V, Atkocius V, Ofomala R. Radiation exposure received by the medical radiation workers in Lithuania at Institute of Oncology, Vilnius University, 2004-2011. Radiat Prot Dosimetry. 2013 Nov;157(1):152-7. doi: 10.1093/rpd/nct111. (IF=0,861)
  5. Schveigert D, Cicenas S, Bruzas S, Samalavicius NE, Gudleviciene Z, Didziapetriene J. The value of MMP-9 for breast and non-small cell lung cancer patients‘ survival. Adv Med Sci. 2013;58(1):73-82. doi: 10.2478/v10039-012-0066-y. (IF=0,964)
  6. Schveigert D, Valuckas KP, Kovalcis V, Ulys A, Chvatovic G, Didziapetriene J. Significance of MMP-9 expression and MMP-9 polymorphism in prostate cancer. Tumori. 2013 Jul-Aug;99(4):523-9. doi: 10.1700/1361.15105. (IF=1,09)



Updated 2020-02-24 15:28